Annabel Samimy
Stock Analyst at Stifel
(3.52)
# 910
Out of 5,008 analysts
49
Total ratings
46.67%
Success rate
36.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $60 → $80 | $73.92 | +8.22% | 2 | Sep 24, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $29.43 | +69.92% | 1 | Jan 8, 2025 | |
| ALT Altimmune | Initiates: Buy | $18 | $4.09 | +340.10% | 1 | Jan 8, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 → $17 | $5.33 | +219.25% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $16.01 | +149.84% | 1 | Oct 8, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $6.75 | +166.67% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $11.14 | +115.44% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $11.82 | +238.41% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $33.52 | +138.66% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $137.92 | +66.76% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $6.29 | +297.46% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $19.86 | +76.23% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $24.60 | +164.23% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 → $275 | $11.45 | +2,302.06% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $38.29 | +17.52% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $120 | $4.38 | +2,642.86% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $0.49 | +4,785.99% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.06 | +70,654.72% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $47.51 | -49.48% | 7 | Apr 16, 2020 |
Palvella Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $60 → $80
Current: $73.92
Upside: +8.22%
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $29.43
Upside: +69.92%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $4.09
Upside: +340.10%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $5.33
Upside: +219.25%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $16.01
Upside: +149.84%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $6.75
Upside: +166.67%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $11.14
Upside: +115.44%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $11.82
Upside: +238.41%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $33.52
Upside: +138.66%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $137.92
Upside: +66.76%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $6.29
Upside: +297.46%
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $19.86
Upside: +76.23%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $24.60
Upside: +164.23%
Jun 26, 2023
Downgrades: Hold
Price Target: $700 → $275
Current: $11.45
Upside: +2,302.06%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $38.29
Upside: +17.52%
Nov 10, 2022
Upgrades: Buy
Price Target: $120
Current: $4.38
Upside: +2,642.86%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $0.49
Upside: +4,785.99%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.06
Upside: +70,654.72%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $47.51
Upside: -49.48%